GSK reaches settlement in US Zantac litigation

The case, brought by California resident James Goetz in Alameda County Superior Court, was to go to trial on July 24 and mark the first test of how Zantac cancer claims will fare before a jury.

It will now be dismissed, GSK said.

First approved in 1983, Zantac became the best-selling medicine in the world in 1988 and one of the first-ever drugs to top $1 billion in annual sales.

In 2019, some manufacturers and pharmacies halted Zantac sales over concerns that its active ingredient, ranitidine, degraded over time to form a chemical called NDMA.

Read also: Sanofi prevails in Zantac arbitration initiated by Boehringer Ingelheim

While NDMA is found in low levels in food and water, it is known to cause cancer in large amounts.

The U.S. Food and Drug Administration in 2020 pulled all remaining brands of Zantac and its generic versions off the market, triggering a wave of lawsuits.

GSK has, however, repeatedly denied that Zantac can cause cancer.